AKRO - Akero Therapeutics, Inc.
IEX Last Trade
28.92
0.120 0.415%
Share volume: 19,203
Last Updated: Thu 26 Dec 2024 08:30:09 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$28.80
0.12
0.42%
Fundamental analysis
21%
Profitability
25%
Dept financing
2%
Liquidity
50%
Performance
15%
Performance
5 Days
0.67%
1 Month
-8.34%
3 Months
-2.66%
6 Months
24.55%
1 Year
20.40%
2 Year
-41.54%
Key data
Stock price
$28.92
DAY RANGE
$27.93 - $29.04
52 WEEK RANGE
$18.28 - $37.00
52 WEEK CHANGE
$18.90
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Andrew Cheng
Region: US
Website: akerotx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: akerotx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Akero Therapeutics, Inc. engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins.
Recent news